REVIEW ARTICLE

Fanconi anaemia

M D Tischkowitz, S V Hodgson

J Med Genet 2003;40:1–10

Fanconi anaemia (FA) is an autosomal recessive disease characterised by congenital abnormalities, defective haemopoiesis, and a high risk of developing acute myeloid leukaemia and certain solid tumours.

Chromosomal instability, especially on exposure to alkylating agents, may be shown in affected subjects and is the basis for a diagnostic test. FA can be caused by mutations in at least seven different genes.

Interaction pathways have been established, both between the FA proteins and other proteins involved in DNA damage repair, such as ATM, BRCA1 and BRCA2, thereby providing a link with other disorders in which defective DNA damage repair is a feature. This review summarises the clinical features of FA and the natural history of the disease, discusses diagnosis and management, and puts the recent molecular advances into the context of the cellular and clinical FA phenotype.

cloned (*FANCA*, *C*, *D2*, *E*, *F*, *G*),^{6–12} and a recent report has shown that *FANCD1* and possibly also *FANCB* are actually *BRCA2*.¹³ As a result of these findings, the study of FA protein interactions has become possible and functional pathways between the FA proteins and other proteins involved in DNA repair have been established.^{14–16} This review will summarise the clinical features of FA, discuss diagnosis and management, and explain how the recent molecular advances have helped us understand the cellular and clinical phenotype.

EPIDEMIOLOGY

The incidence of FA is approximately three per million and the heterozygote frequency is estimated at 1 in 300 in Europe and the United States.^{17,18} FA has been reported in many ethnic groups¹⁹ and founder mutations have been described in Ashkenazi Jews, who have an approximate carrier frequency of 1 in 89,²⁰ and Afrikaners where the carrier frequency was estimated at 1 in 83.²¹

CLINICAL FEATURES

Congenital abnormalities

FA is a very heterogeneous condition clinically and patients can have a wide variety of abnormalities (table 1).^{22,23}

Of the skeletal abnormalities, radial ray defects such as hypoplasia of the thumbs and radial hypoplasia are the most common (figs 1A, 2A, B); other skeletal defects which may occur include congenital hip dislocation, scoliosis, and vertebral anomalies. Affected subjects often have generalised skin hyperpigmentation, café au lait spots, and areas of hypopigmentation (fig 1B). FA is associated with altered growth both in utero and postnatally. Low birth weight is common and the median height of FA patients lies around the 5th centile. This can sometimes be related to growth

Fanconi anaemia (FA) is an autosomal recessive condition first described in 1927 by the Swiss paediatrician Guido Fanconi,¹ who described a familial form of aplastic anaemia in three brothers with short stature, hypogonadism and skin pigmentation. Since then, over 900 cases have been reported² enabling the disease to be clearly defined. FA cells are characterised by chromosomal hypersensitivity to cross linking agents³ and the resulting increase in chromosome breakage provides the basis for a diagnostic test.⁴ Complementation analysis by cell fusion and correction of cross linker hypersensitivity has delineated at least eight complementation groups (FA-A, B, C, D1, D2, E, F, G),⁵ six genes have been

See end of article for authors' affiliations

Correspondence to:
Dr M D Tischkowitz,
Division of Medical and
Molecular Genetics, GKT
School of Medicine, 8th
Floor, Guy's Tower, Guy's
Hospital, St Thomas' Street,
London SE1 9RT, UK;
marc.tischkowitz@kcl.ac.uk

Table 1 Frequency of abnormalities in FA (taken from Dokal, 2000¹³¹)

Abnormality	Frequency (%)
Skeletal (radial ray, hip, vertebral scoliosis, rib)	71
Skin pigmentation (café au lait, hyper- and hypopigmentation)	64
Short stature	63
Eyes (microphthalmia)	38
Renal and urinary tract	34
Male genital	20
Mental retardation	16
Gastrointestinal (eg, anorectal, duodenal atresia)	14
Cardiac abnormalities	13
Hearing	11
Central nervous system (eg, hydrocephalus, septum pellucidum)	8
No abnormalities	30

Figure 1 (A) Typical radial ray abnormalities and (B) café au lait patches and hypopigmentation, all common features in FA.

hormone deficiency or hypothyroidism; in a recent prospective study of 54 FA patients, 44% had a subnormal response to growth hormone stimulation and 36% had overt or compensated hypothyroidism.²⁴ Abnormalities of glucose/insulin levels were also common and the authors concluded that while short stature is an integral feature of FA, superimposed endocrinopathies might further impair growth. Microphthalmia, microcephaly, and developmental delay are all features frequently present. Conductive deafness is also relatively common; this can be mild and may or may not be associated with external ear malformations. Renal abnormalities are present in approximately one third of patients and include unilateral renal aplasia, renal hypoplasia, horseshoe kidneys, or double ureters. In males there is a high incidence of genital abnormalities such as hypogenitalia, undescended testes, and hypospadias, and infertility is usual, although there have been reports of males with FA fathering children.²⁵ Females may also have underdeveloped genitalia and uterine anomalies; older females have sparse, irregular menses but can become pregnant if not on androgen therapy.²⁶

Less common abnormalities in FA include gastrointestinal defects such as atresia (oesophageal, duodenal, jejunal), imperforate anus, tracheo-oesophageal fistulae, cardiac defects such as patent ductus arteriosus, ventricular septal defect, pulmonary stenosis, aortic stenosis, and coarctation, and central nervous system defects including hydrocephalus, absent septum pellucidum, and neural tube defects. Apart from isolated immune system abnormalities documented in case reports,²⁷ there is no systematic evidence that FA patients have immune deficiencies before bone marrow failure.

There can be a large degree of phenotypic variability within families, as exemplified by Koc *et al*,²⁸ who described four FA patients from two related consanguineous families who all had the same *FANCA* mutation but exhibited wide variation in

Figure 2 (A, B) A 3½ year old FA child showing radial ray abnormalities. Height and head circumference are both below the 3rd centile.

birth weight, skin pigmentation, and the severity of skeletal, renal, and genital abnormalities. Importantly, up to one third of FA cases do not have any obvious congenital abnormalities,

only being diagnosed when another sib is affected or when they develop haematological problems,²⁹ although most do have some subtle clinical features such as dermatological manifestations. Phenotypes from each complementation group are broadly similar, discussed in more detail later.

Haematological abnormalities

The most important clinical features of FA are haematological; FA is the commonest type of inherited bone marrow failure syndrome and the incidences of aplastic anaemia, myelodysplastic syndrome (MDS), and acute myeloid leukaemia (AML) are all greatly increased in homozygotes. At birth, the blood count is usually normal and macrocytosis is often the first detected abnormality followed by thrombocytopenia and neutropenia. Pancytopenia typically presents between the ages of 5 and 10 years, the median age of onset being 7 years.^{30,31} Clinically, the affected FA patient may present with bleeding, pallor, and/or recurring infections. One study of 388 FA patients calculated the actuarial risk of developing haemopoietic abnormalities and death from haematological causes by the age of 40 to be 98% and 81%, respectively.³¹ The risk of pancytopenia was 84% by the age of 20 years, followed by clonal cytogenetic abnormalities (risk of 67% by 30 years) and MDS or AML (risk of 52% by 40 years). Of the patients studied, 135 (35%) died during the time of the study, the median age of death being 13 years, and the majority (120) died from haematological complications (49 from bone marrow failure, 37 from post transplant treatment related complications, and 34 from MDS or AML). Certain cytogenetic abnormalities are commonly seen in FA patients with MDS/AML, including monosomy 5 and monosomy 7.³⁰ These clonal abnormalities are more often found in sporadic MDS related AML and AML occurring secondary to treatment with alkylating agents.³²

In those affected patients who survive into early adulthood, there is a greatly increased risk of solid tumours, notably hepatic tumours, which may be related to androgen use, and squamous cell carcinomas of the oesophagus, oropharynx, and vulva.²

Studies of cancer risk in FA heterozygotes are conflicting; the initial study by Swift *et al*¹⁸ analysed 102 deaths in the relatives of eight FA cases and found a higher rate of leukaemia and cancers of the tongue, stomach, and large bowel. However, this was not statistically significant and when the study was expanded to 25 families, no overall or specific excess of cancers could be shown and there were fewer leukaemias than expected.³³ A separate study of 125 relatives in nine FA families also failed to show a difference.³⁴

In summary, FA is a highly heterogeneous syndrome; homozygotes can present at birth with congenital abnormalities or during childhood with haemopoietic abnormalities. The main causes of morbidity and mortality are aplastic anaemia, myelodysplasia, acute myeloid leukaemia, and solid tumours at older ages in those surviving the childhood haematological malignancies.

MANAGEMENT OF THE PATIENT WITH FA

Making the diagnosis

Because of the heterogeneous nature of the condition, FA is difficult to diagnose on clinical features. FA cells show increased chromosome breakage but this is highly variable and overlaps with the range for normal cells. Adding DNA cross linking agents such as mitomycin C (MMC)³⁵ or diepoxybutane (DEB)³⁶ increases the number of chromosome breaks with distinct ranges for normal and FA cells, so providing the basis for a diagnostic test.⁴ Chromosome breakage studies can be carried out on amniotic cells, chorion villus cells, or fetal blood and therefore it can be used for prenatal diagnosis.³⁷ Although MMC/DEB testing is highly specific for FA, interpretation is complicated in cases of somatic mosaicism (see Somatic mosaicism section below).

FA patients have an intrinsic cell cycle disturbance consisting of prolonged progression through, and arrest within, the G2 phase compartment of the cell cycle³⁸; flow cytometry of suspected FA patient cells treated with cross linkers can measure this and make the diagnosis with comparable accuracy to chromosome studies.^{39–41} This approach has the advantage that it is less time consuming and does not require cytogenetic expertise. It may also sometimes be helpful when there are discrepancies on DEB testing.⁴² However, it is not reliable in cases with concurrent myelodysplasia or leukaemia.^{40,41} Until recently, there has been no method to determine complementation group apart from time consuming cell fusion assays, but it has now been shown that retroviruses expressing *FANCA*, *FANCC*, or *FANCG* cDNA can be used to correct the phenotype of T cells from FA patients and thereby determine complementation group in a rapid, accurate manner.⁴³

Differential diagnoses

Anomalies such as vertebral defects, tracheo-oesophageal atresia, and renal and radial ray defects found in the sporadic VATER/VACTERL association overlap with those found in FA.

Thrombocytopenia-absent radii (TAR) syndrome, which is autosomal recessive, presents with thrombocytopenia at birth or around the neonatal period and radial ray defects but, unlike FA, thumbs are invariably present bilaterally.^{44,45} Unlike FA, there is no documented increase in haematological or solid tumour malignancies in TAR.

Diamond-Blackfan anaemia is characterised by defective erythroid progenitor maturation and usually presents in the first year of life with normochromic or macrocytic anaemia.⁴⁶ Over one third have congenital malformations, often involving the head (micrognathia, cleft lip), upper limbs, and genitourinary system. It is slightly more common than FA and most cases are sporadic with evidence of autosomal dominant or, less frequently, recessive inheritance.

In all three conditions, MMC/DEB testing is within normal parameters, allowing confident differentiation from FA.

Nijmegen breakage syndrome (NBS) is a rare autosomal recessive disorder resulting from mutations in *NBS1*, which codes for the nibrin protein.⁴⁷ It is characterised by immune deficiency, microcephaly, and hypersensitivity to ionising radiation and the majority of patients are of Slav origin and are homozygous for a single mutation in the *NBS* gene (657del5), suggesting a founder effect.^{47,48} A recent study of NBS in eight Russian patients found three to have haemopoietic abnormalities or AML.⁴⁹ NBS can therefore closely mimic FA at the clinical level, and testing for NBS mutations should be considered if there is any doubt regarding the diagnosis of FA.

Somatic mosaicism

In haemopoietic cells of FA patients, somatic mosaicism may result in the reversion from the pathogenic allele to the wild type, resulting in the disease phenotype reverting back to normal in the relevant cell clones; 10–25% of FA patients will have such mixed lymphocyte populations and this can create difficulty in interpreting diagnostic chromosome breakage tests. This is exemplified by a case of two affected brothers who had known *FANCC* mutations but only one a positive DEB test.⁵⁰ Thus, somatic mosaicism could be one explanation for intrafamilial phenotypic variation in FA.

The exact mechanism for somatic mosaicism can vary; one mechanism involves mitotic recombination in a bone marrow stem cell, resulting in both FA mutations on the same allele while the other allele becomes functional.⁵¹ Other observed mechanisms include spontaneous genotypic reversion⁵² and functional correction of the mutation as a result of secondary sequence alterations in *cis*.⁵³ All may confer a selective advantage to the cell, which then repopulates the marrow and could

Table 2 The FA genes

	Gene frequency (%)	Chromosomal location	Exons	Amino acids	Molecular weight (kDa)	Reference
<i>FANCA</i>	66	16q24.3	43	1455	163	6, 7
<i>(FANCB)*</i>	<1					
<i>FANCC</i>	12	9q22.3	14	557	63	8
<i>(FANCD1)*</i>	<1					
<i>FANCD2</i>	<1	3p25.3	44	1451	155/162	9
<i>FANCE</i>	4	6p21-22	10	536		11
<i>FANCF</i>	4	11p15	1	374	42	10
<i>FANCG</i>	12	9p13	14	622	68	12

**FANCB* and *FANCD1* are now thought to be *BRCA2*.¹³

lead to improved haemopoiesis. While some FA somatic mosaics do have a milder haematological phenotype,⁵¹ this is not always the case.

Initial management

If a diagnosis of FA is suspected, it should be confirmed by chromosome breakage studies using DEB or MMC. The family should be referred to a clinical geneticist and other sibs should be examined and offered DEB/MMC testing. Management thereafter depends on the age of presentation and the absence or presence of haematological abnormalities. All patients should have an ultrasound of the renal tract, hearing tests, and a haematological assessment that should include examination of the bone marrow. HLA typing in anticipation of possible bone marrow transplantation should be performed. An endocrinological assessment should also be made, especially if there is evidence of growth failure, and an ophthalmological assessment may show specific eye defects such as microphthalmia, almond shaped palpebral fissures, and epicanthic folds. Hand surgeons and plastic surgeons may consider correcting radial ray defects with a view to improving function and appearance.

Haematological management

If there is no haemopoietic defect at the time of diagnosis, haematological monitoring may only be required once per year but as the patient becomes older and develops haematological complications, haematologists play an increasingly central role. Many patients who develop bone marrow failure initially respond to supportive measures such as blood transfusions, androgens, and cytokines.⁵⁴

Androgens, usually oral oxymethalone, are often used therapeutically because they enhance production and urinary excretion of erythropoietin and increase bone marrow cellularity.⁵⁵ If the patient responds, the dose should be tapered over a period of three months to reduce side effects which include masculinisation, acne, hyperactivity, growth spurt followed by premature closure of the epiphyses resulting in short stature, deranged liver enzymes, hepatic adenomas, and potential risk of hepatic adenocarcinomas. Monitoring of liver function (liver enzymes, bilirubin, alpha-fetoprotein every two to three months and yearly liver ultrasound scans) is mandatory while on androgen therapy. Cytokines such as G-CSF and GM-CSF can improve haemopoiesis either in conjunction with androgens (particularly if the patient is neutropenic) or if androgens have failed. They should not be used in patients with clonal cytogenetic abnormalities and should be discontinued if such abnormalities develop while on therapy because of the potential risk of inducing leukaemia. Eventually most patients become refractory to therapy and the definitive treatment of choice is haemopoietic stem cell transplantation (SCT). Since it was found that cells from FA patients are more sensitive to radiation⁵⁶ and conditioning agents such as cyclophosphamide,⁵⁷ this has been carried out using greatly reduced doses, giving a two year survival rate of

70%.⁵⁸ Alternative conditioning regimens using fludarabine and avoiding irradiation have shown promising results so far.⁵⁹ For those patients without matched sibs, the prognosis for unrelated donors is less good at around 20-40% survival at two years and there is a higher risk of graft rejection in somatic mosaics.⁶⁰

Recently, preimplantation genetic diagnosis (PGD) for parents of a previously affected child has been used to select embryos that were both unaffected with FA and HLA matched to their affected sib with a view to performing a SCT using umbilical cord blood. The procedure has been successful but required multiple attempts, led to wastage of otherwise healthy embryos (those that were unaffected but HLA mismatched), and is therefore still regarded as ethically controversial.⁶¹⁻⁶²

Subsequent management

For those affected subjects who survive the haematological complications, follow up surveillance for solid malignancies becomes increasingly important.² A study of secondary cancers in 700 aplastic anaemia patients who received an allogeneic bone marrow transplant highlighted FA as an independent risk factor for developing malignancy with a predicted risk of 42% at 20 years after transplant.⁶³ Females should have annual gynaecological follow up to detect cervical and vulval tumours and both sexes should be kept under surveillance for oropharyngeal, oesophageal, and hepatic tumours. While there have been reports of increased radiation sensitivity in FA patients having radiotherapy for cancer treatment,⁶⁴⁻⁶⁵ this is not a consistent finding⁶⁶ and cancer management based on the current limited evidence from FA patients should maximise surgical intervention while keeping chemotherapy and radiotherapy use to a minimum.

The multiple problems in early age, subsequent requirement for SCT, and continuing poor prognosis in survivors because of cancer susceptibility puts a great psychological strain on the FA patient and their family. Adequate psychosocial support and the involvement of a coordinated, multidisciplinary team with specialist knowledge are cornerstones to successful management of these patients.

Gene therapy

FA is an ideal candidate disease for gene therapy in view of the serious haematological complications requiring SCT and the likelihood that corrected FA cells have a selective advantage over defective ones, suggested by the high observed incidence of somatic mosaicism in FA patients. There have been successful attempts using retroviral mediated gene transfer in *FANCC* knockout mice which led to phenotypic correction of MMC sensitivity.⁶⁷ Clinical trials so far in humans using retroviral vectors have been disappointing,⁶⁸ but the recent use of lentiviral vectors in knockout mice has given promising results; efficient transduction could be attained using low viral dose, without cytokine prestimulation and minimal ex vivo manipulation, and may therefore be more successful than retroviruses in human therapy.⁶⁹

Figure 3 A schematic diagram showing FA protein complex and the central role of *FANCD2* in the DNA damage response pathway based on Taniguchi *et al*¹⁵ and Witt and Ashworth.¹⁶ DNA damage caused by cross linking agents such as MMC activates the FA protein complex leading to monoubiquitination of *FANCD2*, which interacts with *BRCA1* to effect DNA repair. Damage caused by ionising radiation activates ATM which phosphorylates *FANCD2* in addition to several other proteins to coordinate the S phase checkpoint response.

GENETICS

Until recently, there were thought to be at least eight FA complementation groups determined by somatic cell hybridisation, FA-A, B, C, D1, D2, E, F, G. Six of the FA genes (*FANCA*, *C*, *D2*, *E*, *F*, *G*) have been cloned and it now appears that *FANCD1* and possibly also *FANCB* are in fact *BRCA2*¹³ (table 2). A further complementation group, FA-H, has subsequently been shown to belong to the FA-A complementation group.⁷⁰ *FANCA* mutations are the most prevalent, accounting for approximately two-thirds of all cases, *FANCC* and *FANCG* account for 25% of cases, *FANCE* and *FANCF* a further 8%, and the other groups less than 1%. None of the genes that have been cloned bear any homology to each other or to known DNA repair genes. Knockout mice have been generated for *FANCA*,⁷¹ *FANCC*,⁷² and *FANCG*.⁷⁴ All display a similar phenotype; they are viable, have no detectable developmental abnormalities, and do not develop any serious haematological complications or malignancies, although they do show a similar cellular phenotype to human FA patients, exhibiting spontaneous chromosomal instability and hypersensitivity to MMC. Both male and female mice show hypogonadism and impaired fertility.

THE FA GENES

FANCA was cloned in 1996^{6,7} and it is one of the largest FA genes. Over 100 different mutations have been reported⁷⁵⁻⁷⁸ with 30% point mutations, 30% 1-5 base pair microdeletions or microinsertions, and 40% large deletions, removing up to 31 exons from the gene.⁷⁷ Small duplications have also been reported.⁷⁸ The large deletions often occur at specific breakpoints and have been shown to arise as a result of *Alu* mediated recombination.⁷⁷⁻⁸¹ The heterogeneity of *FANCA* mutations and the fact that most patients are compound heterozygotes makes diagnostic screening for mutations difficult. Mutation analysis is less complex in populations where founder mutations have been described, such as the deletion exon 12-31 mutation, which accounts for 60% of mutations in Afrikaners.⁸¹

FANCA is ubiquitously expressed at low levels in all cells⁸² in both nucleus and cytoplasm,⁸³ corresponding with its putative caretaker role within the cell.

FANCC was the first gene to be cloned by functional complementation in 1992⁸ and compared to *FANCA* there is a much smaller spectrum of mutations. The most frequent is the intronic mutation IVS4+4A→T which leads to an altered splice site and deletion of exon 4; this is particularly prevalent in Ashkenazi Jews with a carrier frequency of 1 in 89 and is characterised by a severe phenotype with multiple congenital abnormalities and earlier onset of bone marrow failure.^{84,85} Interestingly, the same mutation is also the most prevalent *FANCC* mutation in the Japanese population (thought to be the result of a separate founder mutation), but the phenotype is less severe compared to Ashkenazis, suggesting that race specific modifying genes or environmental factors influence phenotype severity.⁸⁶ Other common mutation sites are found in exon 1 and exon 14. *FANCC* is ubiquitously expressed and the protein has been localised to both cytoplasm and nucleus.⁸⁷

FANCD1 has very recently been shown to be *BRCA2* by sequencing the *BRCA2* gene in cell lines from *FANCD1* patients who were subsequently found to be compound heterozygotes.¹³ *BRCA2*^{-/-} cells exhibit many of the features of FA cells such as chromosomal instability and hypersensitivity to cross linking agents,^{88,89} but null mice are not viable and no humans with biallelic germline *BRCA2* mutations had been reported before, suggesting that this is not normally compatible with life in man. However, at least one of the mutations found in each of the two *FANCD1* patients analysed is in the 3' region of the gene, and it may be that those *BRCA2*^{-/-} subjects expressing truncated *BRCA2* protein with at least partial activity could be viable, and have a FA phenotype. Biallelic *BRCA2* mutations have also been found in the *FANCB* reference cell line, suggesting the possibility of intra-allelic complementation or phenotypic reversion to wild type.⁷⁰

FANCD2 is the most recently cloned gene⁹ and although it accounts for only a very small number of FA families, it plays a key role in the FA pathway. Other FA gene sequences are

conserved at the vertebrate level but *FANCD2* is the only one conserved in lower organisms such as *Drosophila melanogaster*. The *FANCD2* protein exists in two forms, *FANCD2* short (S) and *FANCD2* long (L), the long version being formed by the addition of a ubiquitin molecule to a lysine residue at position 561; upon monoubiquitination, *FANCD2L* is targeted to discrete nuclear foci where it colocalises with *BRCA1*.⁹⁰ FA cells deficient for *FANCD2* are sensitive to MMC but also have a degree of sensitivity to ionising radiation and have a defect in the ionising radiation inducible S phase checkpoint response similar to that seen in ataxia-telangiectasia (AT).¹⁵ When normal cells are exposed to ionising radiation, the AT protein product, ATM, phosphorylates *FANCD2* on serine 222, activating this checkpoint response, a mechanism which is distinct and independent of MMC induced monoubiquitination.¹⁵ *FANCD2* thereby provides a link between the FA protein complex and other pathways implicated in DNA repair by functioning at the intersection of two pathways, one involving MMC inactivation by the FA protein complex and the other involving ionising radiation inactivation by ATM.

The *FANCE* and *FANCF* genes were both cloned by functional complementation^{10,11} and between them account for less than 10% of all FA families. *FANCG* is identical to *XRCC9*,¹² a human gene that corrects chromosomal instability and mutagen sensitivities in Chinese hamster ovary UV40 cells.⁹¹ All types of mutations apart from large deletions have been reported in *FANCG*.⁹²

In a genotype-phenotype study of 245 FA patients from all complementation groups, a more severe cytopenia and higher incidence of leukaemia was detected in the FA-G group, there was an earlier onset of anaemia and a higher incidence of leukaemia in those patients with *FANCA* null mutations, and there was a reduced incidence of somatic abnormalities in the FA-C group excluding the IVS4+4A→T mutation.⁹³ Thus, patients with *FANCG* mutations and *FANCA* null mutations appear to constitute a high risk group.

However, the broad similarities in phenotype between the different FA complementation groups make it likely that the FA protein products interact in a common pathway. This has been confirmed by yeast two hybrid and coimmunoprecipitation studies of *FANCA*, C, G, E, and F that have shown that each of these FA proteins interacts with at least one other. Initially *FANCA* and *FANCC* were shown to interact to form a complex and translocate into the nucleus.⁸⁷ Subsequently *FANCG*, *FANCF*, and *FANCE* were all shown also to be part of this complex.⁹⁴⁻⁹⁶ It has also been shown that *FANCC/A* interactions are disrupted, not only in *FANCC* and *FANCA* cells, but also in *FANCB*, E, F, G cells and not in *FANCD* cells, suggesting that the FA protein complex acts upstream of *FANCD2*.⁹⁷

Current evidence therefore suggests that a core complex composed of *FANCA*, C, E, F, G leads to activation of *FANCD2S* to *FANCD2L* by monoubiquitination (fig 3) and *FANCD2L* may then interact with *BRCA1*. *FANCD2* also interacts independently with ATM activating the S phase checkpoint response. As the *BRCA1* associated genome surveillance complex (BASC) includes DNA damage repair proteins such as ATM, NBS1, MRE11, BLM, and MSH2 (these genes are mutated in ataxia-telangiectasia, Nijmegen breakage syndrome, A-T-like disorder, Bloom's syndrome, and HNPCC respectively), FA may be linked at a molecular level to these other DNA damage repair disorders.⁹⁸⁻¹⁰⁰ The intriguing discovery that *FANCD1* and possibly also *FANCB* are in fact *BRCA2* indicates that the pathways involved in breast cancer susceptibility and FA are interconnected at more than one level.^{13,16}

THE FA FUNCTIONAL PATHWAY

DNA repair in the FA cell

The exact mechanisms that lead to disruption of DNA repair in FA cells remain disputed.^{98,101} Repair of interstrand cross links (ICLs), induced by agents such as DEB and MMC, necessitates

incision of DNA and both strands of DNA are damaged simultaneously so there is no available undamaged template. Double stranded breaks (DSBs) can be repaired by non-homologous end joining (NHEJ) where two DNA ends are ligated together at regions of little or no homology. Studies where plasmid extracts have been introduced into *FANCC* mutated cells have shown a reduced fidelity of non-homologous repair of blunt ended DSBs compared to normal cells, leading to a deletion prone phenotype which can be corrected by complementing the cells with wild type *FANCC*.¹⁰² Similar DSB repair error prone phenotypes have been described in *FANCD1* defective cells,¹⁰³ but also in other chromosome instability syndromes such as Bloom's syndrome, ataxia-telangiectasia, and Werner's syndrome.¹⁰⁴ DSBs are generated during V(D)J recombination in normal cells and fidelity (but not frequency) of V(D)J recombination is reduced in FA cells.¹⁰⁵ By contrast, homologous recombination by sister chromatid exchange does not seem to be defective in FA.¹⁰⁶

In addition to abnormalities in NHEJ, it is possible that the detection of DNA damage in the FA cell is also impaired; there is evidence that the S phase cell cycle checkpoints are altered in that ICLs did not slow down or arrest FA cells in the S phase, with arrest instead occurring at the G2 checkpoint after completion of replication.^{107,108}

These studies, taken together with emerging molecular evidence regarding the FA pathway, *BRCA2* and *FANCD2-BRCA1* interactions, and the well characterised chromosomal instability cellular phenotype, clearly indicate that FA proteins play an important role in DNA repair, which could either be direct involvement in repair of the DNA itself and/or in DNA damage signalling pathways mediating cell cycle checkpoints.

Other functions of FA proteins

In addition to defective DNA repair, a number of other possible causes of the abnormalities found in FA patients have been put forward, discussed in brief below.

Cell cycle control

The G2/M transition in the cell cycle is prolonged in FA cells³⁸ and this is further increased if cells are exposed to cross linking agents or high oxygen concentrations.¹⁰⁹ The G2/M checkpoint is associated with surveillance of the genome and repair of damage before progression to mitosis. This observation could be explained by the fact that FA cells fail to repair DNA damage efficiently and therefore arrest at G2.

Oxygen sensitivity

FA cells exhibit increased oxygen sensitivity and chromosome breakage is reduced in the presence of low ambient oxygen concentrations.^{110,111} Many DNA cross linking agents produce reactive oxygen species (ROS) and it is possible that the sensitivity of FA cells to cross linkers is the result of an impaired ability to counteract ROS. Clarke *et al*¹¹² studied apoptosis in FA-C cells and showed that they behave like normal cells when exposed to MMC at 5% oxygen concentration and were hypersensitive to MMC at 20% oxygen, implying that it is the ROS generated by MMC, rather than the DNA cross link formation that causes toxicity in FA cells. Other lines of evidence come from yeast two hybrid studies which have shown that the *FANCC* protein interacts with NADPH cytochrome p450 reductase¹¹³ and *FANCG* with cytochrome p450 2E1 (CYP2E1),¹¹⁴ both enzymes that produce ROS.

Apoptosis and telomere maintenance

Various studies have shown apoptosis to be abnormally regulated in FA cells although the exact nature of the abnormality remains disputed.¹¹⁵ In one study, treatment of four FA lymphoblastoid cell lines with MMC led to a higher level of apoptosis,¹¹⁶ but other studies have shown higher levels of spontaneous apoptosis, lower levels after gamma irradiation, and no

Table 3 Known FA protein interactions

Interacting proteins	Functional significance	Reference
FANCA with:		
Alpha spectrin II	Scaffold protein involved in repair of interstrand cross links	132, 133
XPF	DNA repair endonuclease	134
SNX5	Receptor trafficking between organelles	135
FANCC with:		
GRP94	Molecular chaperone	136
CDC2	Cell cycle/apoptosis	137, 138
FAZF	Transcription regulator	139
Hsp70	Apoptosis	118
GSTP1	Apoptosis	119
STAT1	Growth/differentiation	140
p450 reductase	Oxygen metabolism	111
FANCD2 with:		
BRCA1	DNA damage repair	88
ATM	Induces S phase checkpoint following ionising radiation	15
FANCG with:		
CYP2E1	Oxygen metabolism	112

difference after MMC.^{117–119} Increased apoptosis may be related to inability of FA cells to repair damage or to defective FA protein interactions with other proteins in the apoptosis pathways.^{120–121} Accelerated telomere shortening has been detected in FA,^{122–123} but is also found in other forms of aplastic anaemia¹²⁴ and in MDS.¹²⁵ This could be explained by a haemopoietic stem cell undergoing a higher than normal number of cell divisions to generate mature end cells, but a recent study has shown that, in addition to replicative shortening, there is also a higher rate of breakage at telomeric sequences in FA cells, suggesting a defect in telomere maintenance.¹²⁶

Haemopoiesis

In vitro bone marrow culture assays have shown defective haemopoiesis in FA¹²⁷ and FA cells show altered levels of certain growth factors, such as reduced IL-6,¹²⁸ GM-CSF,¹²⁹ IL-1 β ,¹³⁰ and increased TNF- α .^{131–132} These may affect haemopoiesis by altering the bone marrow microenvironment, leading to deregulation of cellular homeostasis, differentiation, and response to stress.

Haematopoietic tissue is one of the tissues most sensitive to DNA damage caused by radiation or cytotoxic therapy but while other DNA repair disorders such as xeroderma pigmentosum or ataxia-telangiectasia have an increased risk of certain malignancies, they do not have the same striking incidence of bone marrow failure seen in FA. It therefore seems likely that the FA proteins play a specific critical role in the maintenance of haematopoietic stem cells and that a combination of different functions of the FA pathway are implicated; the initial decline in haematopoietic stem cells leading to bone marrow failure could be the result of defective telomere maintenance and high rates of apoptosis. Then selective pressures may promote mutant clones developing as a result of the altered cytokine signalling environment against a background of genome instability leading to MDS and ultimately AML.¹³³

The elucidation of the precise nature of these additional defects in the context of our current understanding of the interactions of the FA proteins remains a significant challenge, but it is clear that as well as interacting in a complex, at least some of the individual FA proteins interact with proteins in other pathways and are responsible for the cellular phenotypes described above (table 3).

FUTURE DIRECTIONS

With the characterisation of the main FA genes now accomplished, emphasis has moved to studying the overall function of the FA protein complex and interactions with

other DNA repair proteins. Further protein interactions are likely to be found with the more recently cloned FA genes and a core DNA repair pathway involving the FA proteins has emerged. Many questions remain regarding functions of FA proteins outside DNA repair and how these affect phenotype. Correlation between the molecular defect, cellular defect, and clinical manifestation is an important task which will lead to better diagnosis and management of affected subjects with the ultimate goal of developing effective gene therapy. Improved haematological management in the form of specialised regimens for SCT in FA patients and the introduction of drugs such as fludarabine are leading to improved survival of FA patients, but this has resulted in larger numbers of homozygotes reaching the age where they are likely to develop solid tumours and further research will need to be done to determine optimum treatment for these malignancies.

SUMMARY

Fanconi anaemia is a heterogeneous condition that can present with a variety of congenital defects but invariably results in defective haemopoiesis which is the major cause of morbidity and mortality. There have been significant advances in the treatment of the haematological problems through the use of stem cell transplants, but there is a very high risk of oesophageal, vulval, and oropharyngeal tumours in survivors of the haematological complications. Seven main genes causing FA have been identified which will lead to the development of efficient and complete mutation screening, something that will become more important with the advent of preimplantation genetic diagnosis and the possibility of gene therapy. FA can be accurately diagnosed using DEB/MMC induced chromosome breakage which is highly specific. Over recent years much progress has been made in identifying the remaining FA genes, their interactions, and common pathways. The cloning of *FANCD2*, the identification of *FANCD1* (and possibly also *FANCB*) as *BRCA2*, and development of a model for interaction of the other FA genes have linked the complementation groups together. Mounting evidence from cell studies together with the discovered link between *FANCD2*, *BRCA1*, and *ATM* are helping to elucidate the exact nature of the DNA repair deficit in FA and connect FA to the other DNA repair disorders.

ACKNOWLEDGEMENTS

We thank Professor C Mathew for his helpful suggestions and comments during the preparation of this manuscript and Professor E

Gordon-Smith for supplying clinical photographs. MT is funded by Cancer Research UK.

Online resources for FA patients and their clinicians: www.fanconi.org Homepage of the Fanconi Anaemia Research Fund, the US patient support group. www.fanconi-anaemia.co.uk Homepage of the UK Fanconi Anaemia support group.

Authors' affiliations

M D Tischkowitz, S V Hodgson, Division of Medical and Molecular Genetics, GKT School of Medicine, 8th Floor, Guy's Tower, Guy's Hospital, St Thomas' Street, London SE1 9RT, UK

REFERENCES

- 1 **Fanconi G**. Familiaere infantile pernizioosartige Anaemie (pernizioes Blutbild und Konstitution). *Jahrbuch Kinderheild* 1927;**117**:257-80.
- 2 **Alter BP**. Fanconi's anemia and malignancies. *Am J Hematol* 1996;**53**:99-110.
- 3 **Auerbach AD**, Wolman SR. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. *Nature* 1976;**261**:494-6.
- 4 **Auerbach AD**. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. *Exp Hematol* 1993;**21**:731-3.
- 5 **Joenje H**, Oostra AB, Wijker M, Di SFM, Van BCG, Rooimans MA, Ebell W, Van WM, Pronk JC, Buchwald M, Arwert F. Evidence for at least eight Fanconi anemia genes. *Am J Hum Genet* 1997;**61**:940-4.
- 6 **Lo Ten Foe JR**, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, Lightfoot J, Carreau M, Callen DF, Savoia A, Cheng NC, van Berkel CG, Strunk MH, Gille JJ, Pals G, Kruyt FA, Pronk JC, Arwert F, Buchwald M, Joenje H. Expression cloning of a cDNA for the major Fanconi anemia gene, FAA. *Nat Genet* 1996;**14**:320-3.
- 7 **The Fanconi Anemia/Breast Cancer Consortium**. Positional cloning of the Fanconi anemia group A gene. *Nat Genet* 1996;**14**:324-8.
- 8 **Strathdee CA**, Duncan AM, Buchwald M. Evidence for at least four Fanconi anaemia genes including FACC on chromosome 9. *Nat Genet* 1992;**1**:196-8.
- 9 **Timmers C**, Taniguchi T, Hejna J, Reifsteck C, Lucas L, Bruun D, Thayer M, Cox B, Olson S, D'Andrea AD, Moses R, Grompe M. Positional cloning of a novel Fanconi anemia gene, FANCD2. *Mol Cell* 2001;**7**:241-8.
- 10 **de Winter JP**, Rooimans MA, van Der Weel L, van Berkel CG, Alon N, Bosnoyan-Collins L, de Groot J, Zhi Y, Waisfisz Q, Pronk JC, Arwert F, Mathew CG, Scheper RJ, Hoatlin ME, Buchwald M, Joenje H. The Fanconi anemia gene FANCF encodes a novel protein with homology to ROM. *Nat Genet* 2000;**24**:15-16.
- 11 **de Winter JP**, Leveille F, van Berkel CG, Rooimans MA, van der Weel L, Steltenpool J, Demuth I, Morgan NV, Alon N, Bosnoyan-Collins L, Lightfoot J, Leegwater PA, Waisfisz Q, Komatsu K, Arwert F, Pronk JC, Mathew CG, Digweed M, Buchwald M, Joenje H. Isolation of a cDNA representing the Fanconi anemia complementation group E gene. *Am J Hum Genet* 2000;**67**:5.
- 12 **de Winter JP**, Waisfisz Q, Rooimans MA, Van Berkel CGM, Bosnoyan-Collins L, Alon N, Carreau M, Bender O, Demuth I, Schindler D, Pronk JC, Arwert F, Hoehn H, Digweed M, Buchwald M, Joenje H. The Fanconi anemia group G gene FANCG is identical with XRCC9. *Nat Genet* 1998;**20**:281-3.
- 13 **Howlett NG**, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in fanconi anemia. *Science* 2002;**297**:606-9.
- 14 **Joenje H**, Arwert F. Connecting Fanconi anemia to BRCA1. *Nat Med* 2001;**7**:406-7.
- 15 **Taniguchi T**, Garcia-Higuera I, Xu B, Gregory RC, Kim ST, Lane WS, Kastan MB, D'Andrea AD. Convergence of the Fanconi anaemia and ataxia telangiectasia signaling pathways. *Cell* 2002;**109**:459-72.
- 16 **Witt E**, Ashworth A. D-day for BRCA2. *Science* 2002;**297**:534.
- 17 **Schroeder TM**, Tilgen D, Kruger J, Vogel F. Formal genetics of Fanconi's anemia. *Hum Genet* 1976;**32**:257-88.
- 18 **Swift M**. Fanconi's anaemia in the genetics of neoplasia. *Nature* 1971;**230**:370-3.
- 19 **Alter BP**. Clinical features of Fanconi's anaemia. In: Young NS, Alter BP, eds. *Aplastic anemia: acquired and inherited*. Philadelphia: Saunders, 1994:275-308.
- 20 **Verlander PC**, Kaporis A, Liu Q, Zhang Q, Seligsohn U, Auerbach AD. Carrier frequency of the IVS4 + 4 A→T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. *Blood* 1995;**86**:4034-8.
- 21 **Rosendorff J**, Bernstein R, Macdougall L, Jenkins T. Fanconi anemia: another disease of unusually high prevalence in the Afrikaans population of South Africa. *Am J Med Genet* 1987;**27**:793-7.
- 22 **Auerbach A**, Buchwald M, Joenje H. Fanconi anaemia. In: Vogelstein B, Kinzler KW, eds. *The genetic basis of human cancer*. New York: McGraw Hill, 1999:317-32.
- 23 **De Kerviler E**, Guerazzi A, Zagdanski AM, Gluckman E, Fria J. The clinical and radiological features of Fanconi's anaemia. *Clin Radiol* 2000;**55**:340-5.
- 24 **Wajnrajch MP**, Gertner JM, Huma Z, Popovic J, Lin K, Verlander PC, Batish SD, Giampietro PF, Davis JG, New MI, Auerbach AD. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. *Pediatrics* 2001;**107**:744-54.
- 25 **Liu JM**, Auerbach AD, Young NS. Fanconi anemia presenting unexpectedly in an adult kindred with no dysmorphic features. *Am J Med* 1991;**91**:555-7.
- 26 **Alter BP**, Frizzera CL, Halperin DS, Freedman MH, Chitkara U, Alvarez E, Lynch L, Adler-Brecher B, Auerbach AD. Fanconi's anaemia and pregnancy. *Br J Haematol* 1991;**77**:410-18.
- 27 **Kaplan MJ**, Sabio H, Wanebo HJ, Cantrell RW. Squamous cell carcinoma in the immunosuppressed patient: Fanconi's anemia. *Laryngoscope* 1985;**95**:771-5.
- 28 **Koc A**, Pronk JC, Alikasifoglu M, Joenje H, Altay C. Variable pathogenicity of exon 43del (FAA) in four Fanconi anaemia patients within a consanguineous family. *Br J Haematol* 1999;**104**:127-30.
- 29 **Giampietro PF**, Verlander PC, Davis JG, Auerbach AD. Diagnosis of Fanconi anemia in patients without congenital malformations: an International Fanconi Anemia Registry study. *Am J Med Genet* 1997;**68**:58-61.
- 30 **Auerbach AD**, Allen RG. Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. *Cancer Genet Cytogenet* 1991;**51**:1-12.
- 31 **Butturini A**, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. *Blood* 1994;**84**:1650-5.
- 32 **Head DR**. Revised classification of acute myeloid leukemia. *Leukemia* 1996;**10**:1826-31.
- 33 **Swift M**, Caldwell RJ, Chase C. Reassessment of cancer predisposition of Fanconi anemia heterozygotes. *J Natl Cancer Inst* 1980;**65**:863-7.
- 34 **Potter NU**, Sarmousakis C, Li FP. Cancer in relatives of patients with aplastic anemia. *Cancer Genet Cytogenet* 1983;**9**:61-5.
- 35 **German J**, Schonberg S, Caskie S, Warburton D, Falk C, Ray JH. A test for Fanconi's anemia. *Blood* 1987;**69**:1637-41.
- 36 **Auerbach AD**. A test for Fanconi's anemia. *Blood* 1988;**72**:366-7.
- 37 **Auerbach AD**, Sagi M, Adler B. Fanconi anemia: prenatal diagnosis in 30 fetuses at risk. *Pediatrics* 1985;**76**:794-800.
- 38 **Dutrillaux B**, Aurias A, Dutrillaux AM, Buriot D, Prieur M. The cell cycle of lymphocytes in Fanconi anemia. *Hum Genet* 1982;**62**:327-32.
- 39 **Schindler D**, Kubbies M, Hoehn H, Schinzel A, Rabinovitch PS. Presymptomatic diagnosis of Fanconi's anemia. *Lancet* 1985;**i**:937.
- 40 **Seyschab H**, Friedl R, Sun Y, Schindler D, Hoehn H, Hentze S, Schroeder-Kurth T. Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. *Blood* 1995;**85**:2233-7.
- 41 **Berger R**, Le Coniat M, Gendron MC. Fanconi anemia. Chromosome breakage and cell cycle studies. *Cancer Genet Cytogenet* 1983;**69**:13-16.
- 42 **Toraldo R**, Canino G, Tolone C, D'Avanzo M, Porfirio B, Hoehn H, Schroeder-Kurth T, Pistoia V. Variable response to the diepoxybutane test in two dizygotic twins with Fanconi's anemia and flow cytometry for diagnosis confirmation. *Pediatr Hematol Oncol* 1998;**15**:45-54.
- 43 **Hanenbergh H**, Batish SD, Pollak KE, Vieten L, Verlander PC, Leurs C, Cooper RJ, Gottsche K, Haneline L, Clapp DW, Lobitz S, Williams DA, Auerbach AD. Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. *Exp Hematol* 2002;**30**:410-20.
- 44 **Hall JG**. Thrombocytopenia and absent radius (TAR) syndrome. *J Med Genet* 1987;**24**:79-83.
- 45 **Hedberg VA**, Lipton JM. Thrombocytopenia with absent radii. A review of 100 cases. *Am J Pediatr Hematol Oncol* 1988;**10**:51-64.
- 46 **Dianzani I**, Garelli E, Ramenghi U. Diamond-Blackfan anaemia: an overview. *Paediatr Drugs* 2000;**2**:345-55.
- 47 **Varon R**, Vissinga C, Platzer M, Cerosaletti KM, Chrzanoska KH, Saar K, Beckmann G, Seemanova E, Cooper PR, Nowak NJ, Stumm M, Weemaes CM, Gatti RA, Wilson RK, Digweed M, Rosenthal A, Sperling K, Concannon P, Reis A. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. *Cell* 1998;**93**:467-76.
- 48 **Cerosaletti KM**, Lange E, Stringham HM, Weemaes CM, Smeets D, Solder B, Belohradsky BH, Taylor AM, Karnes P, Elliott A, Komatsu K, Gatti RA, Boehnke M, Concannon P. Fine localization of the Nijmegen breakage syndrome gene to 8q21: evidence for a common founder haplotype. *Am J Hum Genet* 1998;**63**:125-34.
- 49 **Resnick IB**, Kondratenko I, Togoev O, Vasserman N, Shagina I, Evgrafov O, Tverskaya S, Cerosaletti KM, Gatti RA, Concannon P. Nijmegen breakage syndrome: clinical characteristics and mutation analysis in eight unrelated Russian families. *J Pediatr* 2002;**140**:355-61.
- 50 **Dokal I**, Chase A, Morgan NV, Coulthard S, Hall G, Mathew CG, Roberts I. Positive diepoxybutane test in only one of two brothers found to be compound heterozygotes for Fanconi's anaemia complementation group C mutations. *Br J Haematol* 1996;**93**:813-18.
- 51 **Lo Ten Foe JR**, Kwee ML, Rooimans MA, Oostra AB, Veerman AJ, van Weel M, Pauli RM, Shahidi NT, Dokal I, Roberts I, Altay C, Gluckman E, Gibson RA, Mathew CG, Arwert F, Joenje H. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. *Eur J Hum Genet* 1997;**5**:137-48.
- 52 **Gregory JJ Jr**, Wagner JE, Verlander PC, Levan A, Batish SD, Eide CR, Steffenhagen A, Hirsch B, Auerbach AD. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. *Proc Natl Acad Sci USA* 2001;**98**:2532-7.
- 53 **Waisfisz Q**, Morgan NV, Savino M, de Winter JP, van Berkel CG, Hoatlin ME, Lanzano L, Gibson RA, Arwert F, Savoia A, Mathew CG, Pronk JC, Joenje H. Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. *Nat Genet* 1999;**22**:379-83.

- 54 **Rackoff WD**. Treatment of bone marrow failure. In: Owen J, ed. *Fanconi anemia - standards for clinical care*. Fanconi Anemia Research Fund Inc, 1902 Jefferson Street, Suite 2, Eugene, Oregon 97405, 1999:9-20.
- 55 **Pavlatos AM**, Fultz O, Monberg MJ, Vootkur A, Pharm D. Review of oxymetholone: a 17 α -alkylated anabolic-androgenic steroid. *Clin Ther* 2001;**23**:789-801; discussion 771.
- 56 **Gluckman E**. Radiosensitivity in Fanconi anemia: application to the conditioning for bone marrow transplantation. *Radiother Oncol* 1990;**18**(suppl 1):88-93.
- 57 **Berger R**, Bernheim A, Gluckman E, Gisselbrecht C. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. *Br J Haematol* 1980;**45**:565-8.
- 58 **Guardiola P**, Socie G, Pasquini R, Dokal I, Ortega JJ, van Weel-Sipman M, Marsh J, Locatelli F, Souillet G, Cahn JY, Ljungman P, Miniero R, Shaw J, Vermeylen C, Archimbaud E, Bekassy AN, Krivan G, Di Bartolomeo P, Bacigalupo AL, Gluckman E. Allogeneic stem cell transplantation for Fanconi anaemia. Severe Aplastic Anaemia Working Party of the EBMT and EUPAF. European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant* 1998;**21**(suppl 2):S24-7.
- 59 **McCloy M**, Almeida A, Daly P, Vulliamy T, Roberts IA, Dokal I. Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation. *Br J Haematol* 2001;**112**:427-9.
- 60 **MacMillan ML**, Auerbach AD, Davies SM, Defor TE, Gillio A, Giller R, Harris R, Cairo M, Dusenbery K, Hirsch B, Ramsay NK, Weisdorf DJ, Wagner JE. Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial. *Br J Haematol* 2000;**109**:121-9.
- 61 **Verlinsky Y**, Rechitsky S, Schoolcraft W, Strom C, Kuliev A. Preimplantation diagnosis for Fanconi anemia combined with HLA matching. *JAMA* 2001;**285**:3130-3.
- 62 **Damewood MD**. Ethical implications of a new application of preimplantation diagnosis. *JAMA* 2001;**285**:3143-4.
- 63 **Deeg HJ**, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, Sullivan KM, Gluckman E, Storb R. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. *Blood* 1996;**87**:386-92.
- 64 **Gluckman E**, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. *Br J Haematol* 1983;**54**:431-40.
- 65 **Marcou Y**, D'Andrea A, Jeggo PA, Plowman PN. Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. *Radiother Oncol* 2001;**60**:75-9.
- 66 **Alter BP**. Radiosensitivity in Fanconi's anemia patients. *Radiother Oncol* 2002;**62**:345-7.
- 67 **Gush KA**, Fu KL, Grompe M, Walsh CE. Phenotypic correction of Fanconi anemia group C knockout mice. *Blood* 2000;**95**:700-4.
- 68 **Liu JM**, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, Leitman SF, Pensiero M, Young NS, Walsh CE. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). *Hum Gene Ther* 1999;**10**:2337-46.
- 69 **Galimi F**, Noll M, Kanazawa Y, Lax T, Chen C, Grompe M, Verma IM. Gene therapy of Fanconi anaemia by lentivectors. *Blood* 2002;**100**:2732-6.
- 70 **Joenje H**, Levitus M, Waisfisz Q, D'Andrea A, Garcia-Higuera I, Pearson T, van Berkel CG, Rooimans MA, Morgan N, Mathew CG, Arwert F. Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A. *Am J Hum Genet* 2000;**67**:759-62.
- 71 **Cheng NC**, van De Vrugt HJ, van Der Valk MA, Oostra AB, Krimpenfort P, de Vries Y, Joenje H, Berns A, Arwert F. Mice with a targeted disruption of the Fanconi anemia homolog FANCA. *Hum Mol Genet* 2000;**9**:1805-11.
- 72 **Chen M**, Tomkins DJ, Auerbach W, McKlerie C, Yousoufian H, Liu L, Gan O, Carreau M, Auerbach A, Groves T, Guidos CJ, Freedman MH, Cross J, Percy DH, Dick JE, Joyner AL, Buchwald M. Inactivation of Fc in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. *Nat Genet* 1996;**12**:448-51.
- 73 **Whitney MA**, Royle G, Low MJ, Kelly MA, Axthelm MK, Reifsteck C, Olson S, Braun RE, Heinrich MC, Rathbun RK, Bagby GC, Grompe M. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. *Blood* 1996;**88**:49-58.
- 74 **Koomen M**, Cheng NC, van De Vrugt HJ, Godthelp BC, van Der Valk MA, Oostra AB, Zdzienicka MZ, Joenje H, Arwert F. Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice. *Hum Mol Genet* 2002;**11**:273-81.
- 75 **Levrano O**, Erlich T, Magdalena N, Gregory JJ, Batish SD, Verlander PC, Auerbach AD. Sequence variation in the Fanconi anemia gene FAA. *Proc Natl Acad Sci USA* 1997;**94**:13051-6.
- 76 **Wijker M**, Morgan NV, Herterich S, van Berkel CG, Tipping AJ, Gross HJ, Gille JJ, Pals G, Savino M, Altay C, Mohan S, Dokal I, Cavenagh J, Marsh J, van Weel M, Ortega JJ, Schuler D, Samochatova E, Karwacki M, Bekassy AN, Abecasis M, Ebell W, Kwee ML, de Ravel T, et al. Heterogeneous spectrum of mutations in the Fanconi anemia group A gene. *Eur J Hum Genet* 1999;**7**:52-9.
- 77 **Morgan NV**, Tipping AJ, Joenje H, Mathew CG. High frequency of large intragenic deletions in the Fanconi anemia group A gene. *Am J Hum Genet* 1999;**65**:1330-41.
- 78 **Savino M**, Lanzano L, Strippoli P, Ramenghi U, Arslanian A, Bagnara GP, Joenje H, Zelante L, Savoia A. Mutations of the Fanconi anemia group A gene (FAA) in Italian patients. *Am J Hum Genet* 1997;**61**:1246-53.
- 79 **Centra M**, Memmo E, d'Apolito M, Savino M, Lanzano L, Notarangelo A, Liu J, Doggett NA, Zelante L, Savoia A. Fine exon-intron structure of the Fanconi anemia group A (FAA) gene and characterization of two genomic deletions. *Genomics* 1998;**51**:463-7.
- 80 **Levrano O**, Doggett NA, Auerbach AD. Identification of Alu-mediated deletions in the Fanconi anemia gene FAA. *Hum Mutat* 1998;**12**:145-52.
- 81 **Tipping AJ**, Pearson T, Morgan NV, Gibson RA, Kuyt LP, Havenga C, Gluckman E, Joenje H, de Ravel T, Jansen S, Mathew CG. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. *Proc Natl Acad Sci USA* 2001;**98**:5734-9.
- 82 **van de Vrugt HJ**, Cheng NC, de Vries Y, Rooimans MA, de Groot J, Scheper RJ, Zhi Y, Hoatlin ME, Joenje H, Arwert F. Cloning and characterization of murine fanconi anemia group A gene: FANCA protein is expressed in lymphoid tissues, testis, and ovary. *Mamm Genome* 2000;**11**:326-31.
- 83 **Walsh CE**, Yountz MR, Simpson DA. Intracellular localization of the Fanconi anemia complementation group A protein. *Biochem Biophys Res Commun* 1999;**259**:594-9.
- 84 **Gillio AP**, Verlander PC, Batish SD, Giampietro PF, Auerbach AD. Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study. *Blood* 1997;**90**:105-10.
- 85 **Yamashita T**, Wu N, Kupfer G, Corless C, Joenje H, Grompe M, D'Andrea AD. Clinical variability of Fanconi anemia (type C) results from expression of an amino terminal truncated Fanconi anemia complementation group C polypeptide with partial activity. *Blood* 1996;**87**:4424-32.
- 86 **Futaki M**, Yamashita T, Yagasaki H, Toda T, Yabe M, Kato S, Asano S, Nakahata T. The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. *Blood* 2000;**95**:1493-8.
- 87 **Kupfer GM**, Näf D, Suliman A, Pulsipher M, D'Andrea AD. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. *Nat Genet* 1997;**17**:487-90.
- 88 **Patel KJ**, Vu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR. Involvement of Brca2 in DNA repair. *Mol Cell* 1998;**1**:347-57.
- 89 **Tutt A**, Gabriel A, Bertwistle D, Connor F, Paterson H, Peacock J, Ross G, Ashworth A. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. *Curr Biol* 1999;**9**:1107-10.
- 90 **Garcia-Higuera I**, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Mol Cell* 2001;**7**:249-62.
- 91 **Liu N**, Lamerdin JE, Tucker JD, Zhou ZQ, Walter CA, Albala JS, Busch DB, Thompson LH. The human XRCC9 gene corrects chromosomal instability and mutagen sensitivities in CHO UV40 cells. *Proc Natl Acad Sci USA* 1997;**94**:9232-7.
- 92 **Demuth I**, Wlodarski M, Tipping AJ, Morgan NV, de Winter JP, Thiel M, Grasl S, Schindler D, D'Andrea AD, Altay C, Kayserili H, Zatterale A, Kunze J, Ebell W, Mathew CG, Joenje H, Sperling K, Digweed M. Spectrum of mutations in the Fanconi anemia group G gene, FANCG/XRCC9. *Eur J Hum Genet* 2000;**8**:861-8.
- 93 **Faivre L**, Guardiola P, Lewis C, Dokal I, Ebell W, Zatterale A, Altay C, Poole J, Stones D, Kwee ML, van Weel-Sipman M, Havenga C, Morgan N, de Winter J, Digweed M, Savoia A, Pronk J, de Ravel T, Jansen S, Joenje H, Gluckman E, Mathew CG. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. *Blood* 2000;**96**:4064-70.
- 94 **Garcia-Higuera I**, Kuang Y, Näf D, Wasik J, D'Andrea AD. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. *Mol Cell Biol* 1999;**19**:4866-73.
- 95 **de Winter JP**, van Der Weel L, de Groot J, Stone S, Waisfisz Q, Arwert F, Scheper RJ, Kruijff FA, Hoatlin ME, Joenje H. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. *Hum Mol Genet* 2000;**9**:2665-74.
- 96 **Medhurst AL**, Huber PA, Waisfisz Q, de Winter JP, Mathew CG. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. *Hum Mol Genet* 2001;**10**:423-9.
- 97 **Waisfisz Q**, de Winter JP, Kruijff FA, de Groot J, van der Weel L, Dijkmans LM, Zhi Y, Arwert F, Scheper RJ, Yousoufian H, Hoatlin ME, Joenje H. A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA. *Proc Natl Acad Sci USA* 1999;**96**:10320-5.
- 98 **Joenje H**, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. *Nat Rev Genet* 2001;**2**:446-57.
- 99 **Moses RE**. DNA damage processing defects and disease. *Annu Rev Genomics Hum Genet* 2001;**2**:41-68.
- 100 **Futaki M**, Liu JM. Chromosomal breakage syndromes and the BRCA1 genome surveillance complex. *Trends Mol Med* 2001;**7**:560-5.
- 101 **Grompe M**, D'Andrea A. Fanconi anemia and DNA repair. *Hum Mol Genet* 2001;**10**:2253-9.
- 102 **Escarceller M**, Buchwald M, Singleton BK, Jeggo PA, Jackson SP, Moustacchi E, Papadopoulos D. Fanconi anemia C gene product plays a role in the fidelity of blunt DNA end-joining. *J Mol Biol* 1998;**279**:375-85.
- 103 **Escarceller M**, Rousset S, Moustacchi E, Papadopoulos D. The fidelity of double strand breaks processing is impaired in complementation groups B and D of Fanconi anemia, a genetic instability syndrome. *Somat Cell Mol Genet* 1997;**23**:401-11.

- 104 **Runger TM**, Sobotta P, Dekant B, Moller K, Bauer C, Kraemer KH. In-vivo assessment of DNA ligation efficiency and fidelity in cells from patients with Fanconi's anemia and other cancer-prone hereditary disorders. *Toxicol Lett* 1993;**67**:309-24.
- 105 **Smith J**, Andrau JC, Kallenbach S, Laquerbe A, Doyen N, Papadopoulos D. Abnormal rearrangements associated with V(D)J recombination in Fanconi anemia. *J Mol Biol* 1998;**281**:815-25.
- 106 **Novotna B**, Goetz P, Surkova NI. Effects of alkylating agents on lymphocytes from controls and from patients with Fanconi's anemia. Studies of sister chromatid exchanges, chromosome aberrations, and kinetics of cell division. *Hum Genet* 1979;**49**:41-50.
- 107 **Sala-Trepal M**, Rouillard D, Escarceller M, Laquerbe A, Moustacchi E, Papadopoulos D. Arrest of S-phase progression is impaired in Fanconi anemia cells. *Exp Cell Res* 2000;**260**:208-15.
- 108 **Centurion SA**, Kuo HR, Lambert WC. Damage-resistant DNA synthesis in Fanconi anemia cells treated with a DNA cross-linking agent. *Exp Cell Res* 2000;**260**:216-21.
- 109 **Hoehn H**, Kubbies M, Schindler D, Poot M, Rabinovitch PS. BrdU-Hoechst flow cytometry links the cell kinetic defect of Fanconi anaemia to oxygen hypersensitivity. In: Schroeder-Kurth TM, Auerbach AD, Obe G, eds. *Fanconi anaemia: clinical, cytogenetic and experimental aspects*. Berlin: Springer-Verlag, 1989:162-73.
- 110 **Joenje H**, Arwert F, Eriksson AW, de Koning H, Oostra AB. Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. *Nature* 1981;**290**:142-3.
- 111 **Joenje H**, Gille JJP. Oxygen metabolism and chromosomal breakage in Fanconi anaemia. In: Schroeder-Kurth TM, Auerbach AD, Obe G, eds. *Fanconi anaemia: clinical, cytogenetic and experimental aspects of Fanconi anaemia*. Berlin: Springer-Verlag, 1989:174-82.
- 112 **Clarke AA**, Philpott NJ, Gordon-Smith EC, Rutherford TR. The sensitivity of Fanconi anaemia group C cells to apoptosis induced by mitomycin C is due to oxygen radical generation, not DNA crosslinking. *Br J Haematol* 1997;**96**:240-7.
- 113 **Kruyt FAE**, Hoshino T, Liu JM, Joseph P, Jaiswal AK, Yousoufian H. Abnormal microsomal detoxification implicated in Fanconi anemia group C by interaction of the FAC protein with NADPH cytochrome P450 reductase. *Blood* 1998;**92**:3050-6.
- 114 **Futaki M**, Igarashi T, Watanabe S, Kajigaya S, Tatsuguchi A, Wang J, Liu JM. The FANCG Fanconi anemia protein interacts with CYP2E1: possible role in protection against oxidative DNA damage. *Carcinogenesis* 2002;**23**:67-72.
- 115 **Rosselli F**. Fanconi anaemia syndrome and apoptosis: state of the art. *Apoptosis* 1998;**3**:229-36.
- 116 **Kruyt FA**, Dijkmans LM, Van DBTK, Joenje H. Fanconi anemia genes act to suppress a cross-linker-inducible p53-independent apoptosis pathway in lymphoblastoid cell lines. *Blood* 1996;**87**:938-48.
- 117 **Rosselli F**, Ridet A, Soussi T, Duchaud E, Alapetite C, Moustacchi E. p53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. *Oncogene* 1995;**10**:9-17.
- 118 **Ridet A**, Guillaud C, Duchaud E, Cundari E, Fiore M, Moustacchi E, Rosselli F. Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. *Cancer Res* 1997;**57**:1722-30.
- 119 **Rey JP**, Scott R, Muller H. Apoptosis is not involved in the hypersensitivity of Fanconi anemia cells to mitomycin C. *Cancer Genet Cytogenet* 1994;**75**:67-71.
- 120 **Pang Q**, Keeble W, Christianson TA, Faulkner GR, Bagby GC. FANCC interacts with Hsp70 to protect hematopoietic cells from IFN-gamma/TNF-alpha-mediated cytotoxicity. *EMBO J* 2001;**20**:4478-89.
- 121 **Cumming RC**, Lightfoot J, Beard K, Yousoufian H, O'Brien PJ, Buchwald M. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. *Nat Med* 2001;**7**:814-20.
- 122 **Lefeuire F**, Li X, Guardiola P, Le Roux G, Sergere JC, Richard P, Carosella ED, Gluckman E. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. *Br J Haematol* 1999;**105**:883-93.
- 123 **Hanson H**, Mathew CG, Docherty Z, Mackie Ogilvie C. Telomere shortening in Fanconi anaemia demonstrated by a direct FISH approach. *Cytogenet Cell Genet* 2001;**93**:203-6.
- 124 **Ball SE**, Gibson FM, Rizzo S, Toozee JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. *Blood* 1998;**91**:3582-92.
- 125 **Boulwood J**, Fidler C, Kusec R, Rack K, Elliott PJ, Atoyebi O, Chapman R, Oscier DG, Wainscoat JS. Telomere length in myelodysplastic syndromes. *Am J Hematol* 1997;**56**:266-71.
- 126 **Callen E**, Samper E, Ramirez MJ, Creus A, Marcos R, Ortega JJ, Olive T, Badell I, Blasco MA, Surralles J. Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia. *Hum Mol Genet* 2002;**11**:439-44.
- 127 **Stark R**, Thierry D, Richard P, Gluckman E. Long-term bone marrow culture in Fanconi's anaemia. *Br J Haematol* 1993;**83**:554-9.
- 128 **Rosselli F**, Sanceau J, Wietzerbin J, Moustacchi E. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. I. Involvement of interleukin-6. *Hum Genet* 1992;**89**: 42-8.
- 129 **Stark R**, Andre C, Thierry D, Cherel M, Galibert F, Gluckman E. The expression of cytokine and cytokine receptor genes in long-term bone marrow culture in congenital and acquired bone marrow hypoplasias. *Br J Haematol* 1993;**83**:560.
- 130 **de Cremoux P**, Gluckman E, Podgorniak MP, Menier C, Thierry D, Calvo F, Socie G. Decreased IL-1 beta and TNF alpha secretion in long-term bone marrow culture supernatant from Fanconi's anaemia patients. *Eur J Haematol* 1996;**57**:202-7.
- 131 **Schultz JC**, Shahidi NT. Tumor necrosis factor-alpha overproduction in Fanconi's anemia. *Am J Hematol* 1993;**43**:196-201.
- 132 **Rosselli F**, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. *Blood* 1994;**83**:1216-25.
- 133 **Lensch MW**, Rathbun RK, Olson SB, Jones GR, Bagby GC Jr. Selective pressure as an essential force in molecular evolution of myeloid leukemia clones: a view from the window of Fanconi anemia. *Leukemia* 1999;**13**:1784-9.
- 134 **Dokal I**. The genetics of Fanconi's anaemia. *Baillieres Best Pract Res Clin Haematol* 2000;**13**:407-25.
- 135 **McMahon LW**, Walsh CE, Lambert MW. Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex. *J Biol Chem* 1999;**274**:32904-8.
- 136 **McMahon LW**, Sangerman J, Goodman SR, Kumaresan K, Lambert MW. Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links. *Biochemistry* 2001;**40**:7025-34.
- 137 **Kumaresan KR**, Lambert MW. Fanconi anemia, complementation group A, cells are defective in ability to produce incisions at sites of psoralen interstrand cross-links. *Carcinogenesis* 2000;**21**:741-51.
- 138 **Otsuki T**, Kajigaya S, Ozawa K, Liu JM. SNX5, a new member of the sorting nexin family, binds to the Fanconi anemia complementation group A protein. *Biochem Biophys Res Commun* 1999;**265**:630-5.
- 139 **Hoshino T**, Wang JX, Devetten MP, Iwata N, Kajigaya S, Wise RJ, Liu JM, Yousoufian H. Molecular chaperone GRP94 binds to the Fanconi anemia group C protein and regulates its intracellular expression. *Blood* 1998;**91**:4379-86.
- 140 **Kruyt FA**, Dijkmans LM, Arwert F, Joenje H. Involvement of the Fanconi's anemia protein FAC in a pathway that signals to the cyclin B/cdc2 kinase. *Cancer Res* 1997;**57**:2244-51.
- 141 **Kupfer GM**, Yamashita T, Näf D, Suliman A, Asano S, D'Andrea AD. The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. *Blood* 1997;**90**:1047-54.
- 142 **Hoatlin ME**, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht JD. A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF. *Blood* 1999;**94**:3737-47.
- 143 **Pang Q**, Fagerlie S, Christianson TA, Keeble W, Faulkner G, Diaz J, Rathbun RK, Bagby GC. The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors. *Mol Cell Biol* 2000;**20**:4724-35.